inflammation and lipid regulator with UBA-like and NBR1-like domainsGenealiases: C6orf106 · FP852 · dJ391O22.4
Q-omics provides the consensus-scored ILRUN profile across patient tissues and cancer cell-line models. ILRUN expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ILRUN is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ILRUN RNA expression shows 19,120 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ILRUN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ILRUN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ILRUN survival associations across molecular data types. ILRUN RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ILRUN RNA expression–survival associations across cancer types. High ILRUN expression shows unfavorable associations in COAD, LUSC, PAAD and SKCM, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for ILRUN RNA expression.
This table summarizes ILRUN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ILRUN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ILRUN shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, STAD and CHOL. The HNSC box plot shows higher ILRUN RNA expression in tumor versus normal tissue (log2 FC = +0.941, t-test p < 0.001).
This table shows molecular features associated with ILRUN in patient tissues and cancer cell lines. In patient samples, ILRUN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ILRUN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
